Education
About Us
Working with TipRanks
Follow Us
Halozyme Therapeutics (HALO)
NASDAQ:HALO
HALO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$42.01 - $79.50
Previous CloseN/A
Volume1.23M
Average Volume (3M)2.06M
Market Cap
$8.57B
Enterprise Value$7.42B
Total Cash (Recent Filing)$548.18M
Total Debt (Recent Filing)$1.51B
Price to Earnings (P/E)16.7
Beta0.52
Next Earnings
Nov 10, 2025EPS Estimate
1.61Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.54
Shares Outstanding116,966,000
10 Day Avg. Volume2,206,656
30 Day Avg. Volume2,059,937
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.87
Enterprise Value/Revenue6.29
Enterprise Value/Gross Profit7.48
Enterprise Value/Ebitda9.37
Forecast
1Y Price Target
$74.38Price Target Upside1.42% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
Bulls Say, Bears Say
Bulls Say
Clinical Trials And Revenue GrowthHalozyme has promising late-stage clinical trials progressing, indicating potential continued growth in royalty revenues beyond 2025-26.
Partnerships And AgreementsThe company actively seeks new partnerships or expanded agreements, which could bring in additional milestone fee revenues.
Stock Price TargetAnalyst recommends maintaining a Buy rating on HALO shares and increases the price target to $90, suggesting potential share price appreciation.
Bears Say
CMS Draft GuidanceHALO was downgraded to UP in May following CMS’s release of surprisingly negative 2028 draft guidance on combo drug negotiations.
Patent LitigationFDA approval of Merck's Keytruda Qlex is expected to influence the ongoing patent litigation and enhance Halozyme's patent positioning.
Regulatory RisksRegulatory risks persist, with potential clarity on CMS draft guidance expected.
Halozyme News
HALO FAQ
What was Halozyme Therapeutics’s price range in the past 12 months?
Halozyme Therapeutics lowest stock price was $42.01 and its highest was $79.50 in the past 12 months.
What is Halozyme Therapeutics’s market cap?
Halozyme Therapeutics’s market cap is $8.57B.
When is Halozyme Therapeutics’s upcoming earnings report date?
Halozyme Therapeutics’s upcoming earnings report date is Nov 10, 2025 which is in 40 days.
How were Halozyme Therapeutics’s earnings last quarter?
Halozyme Therapeutics released its earnings results on Aug 05, 2025. The company reported $1.54 earnings per share for the quarter, beating the consensus estimate of $1.244 by $0.296.
Is Halozyme Therapeutics overvalued?
According to Wall Street analysts Halozyme Therapeutics’s price is currently Undervalued.
Does Halozyme Therapeutics pay dividends?
Halozyme Therapeutics does not currently pay dividends.
What is Halozyme Therapeutics’s EPS estimate?
Halozyme Therapeutics’s EPS estimate is 1.61.
How many shares outstanding does Halozyme Therapeutics have?
Halozyme Therapeutics has 116,966,000 shares outstanding.
What happened to Halozyme Therapeutics’s price movement after its last earnings report?
Halozyme Therapeutics reported an EPS of $1.54 in its last earnings report, beating expectations of $1.244. Following the earnings report the stock price went up 2.483%.
Which hedge fund is a major shareholder of Halozyme Therapeutics?
Currently, no hedge funds are holding shares in HALO
Halozyme Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$74.38 (1.42% Upside)
$74.38 (1.42% Upside)
Blogger Sentiment
Bullish
HALO Sentiment 83%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 154.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 0.4%
Last 30 Days ▲ 2.5%
Last 30 Days ▲ 2.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
28.12%
12-Months-Change
Fundamentals
Return on Equity
179.14%
Trailing 12-Months
Asset Growth
4.29%
Trailing 12-Months
Company Description
Halozyme Therapeutics
Halozyme Therapeutics, Inc. (HALO) is a biotechnology company focused on developing and commercializing innovative therapies for patients with unmet medical needs. The company specializes in the field of enzymatic drug delivery and has developed its proprietary ENHANZE™ technology, which enables the subcutaneous delivery of biologics. Halozyme operates primarily in the biopharmaceutical sector, collaborating with other companies to enhance the delivery and efficacy of their therapeutic products. Its core products include the ENHANZE technology platform, which is used by various partners to improve the administration of monoclonal antibodies and other biologics.
HALO Company Deck
HALO Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected strong financial performance with significant revenue and royalty growth, successful share repurchase initiatives, and promising developments in key products and the pipeline. However, challenges remain with ongoing IP litigation with Merck and potential regulatory impacts from CMS guidance. Despite these challenges, the overall sentiment remains positive due to the outweighing positive financial and operational achievements.View all HALO earnings summariesHALO Revenue Breakdown
54.01% Royalties
36.28% Product sales
9.71% Revenues under collaborative agreements
HALO Stock 12 Month Forecast
Average Price Target
$74.38
▲(1.42% Upside)
Technical Analysis
Corcept Therapeutics
―
Ionis Pharmaceuticals
―
Bio-Techne
―
Moderna
―
Roivant Sciences
―
Ownership Overview
1.16% Insiders
32.25% Mutual Funds
37.09% Other Institutional Investors
0.07% Public Companies and Individual Investors